News

Neupharma wins the title

Neupharma wins the title

03 June 2020
Neupharma, one of the finalists for the category "Companies - Health & Pharma" from “Le Fonti Awards”, wins the title "Excellence of the Year - Innovation & Leadership - Medical Devices for Cystic Fibrosis"
NEUPHARMA and PARI are launching the DM PARI Service

NEUPHARMA and PARI are launching the DM PARI Service

01 June 2020
The new area of the website “DM PARI Service” is online and ready to be consulted
NEUPHARMA NEW WEBSITE

NEUPHARMA NEW WEBSITE

07 May 2020
May 7, 2020: NEUPHARMA 2020 SITE IS ONLINE
Neupharma donated FFP2 Masks to Red Cross

Neupharma donated FFP2 Masks to Red Cross

05 May 2020
Imola, 4 May 2020: Imola Red Cross continues a constant activity to face COVID-19 emergency thanks to the community aids.
Neupharma joins the project 'Cuore in Comune'

Neupharma joins the project 'Cuore in Comune'

29 November 2019
Imola, November 2019: Neupharma is proud to have joined this important life-saving initiative for our community

The new Neupharma headquarters

02 September 2019
Imola, 02 September 2019: Neupharma inaugurates the new corporate headquarters in the city centre of Imola.
Industria FELIX Award

Industria FELIX Award

05 July 2019
On 19 June 2019, Neupharma Members collected the prestigious Industria Felix award. The ceremony was organized by the homonymous Cultural Association in collaboration with the CERVED Centre of Economic Studies, and it was held at the LUISS Guido Carli University of Rome.
Neupharma announces the acquisition of 15% of PlumeStars

Neupharma announces the acquisition of 15% of PlumeStars

21 January 2019
Neupharma announces that it has acquired 15% of the PlumeStars Research Company. PlumeStars is based in Parma and is dedicated to the development of orphan products for rare diseases with a specific know-how in inhalation formulations.
The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula

The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula

23 August 2017
The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula for cystic fibrosis, a formula developed by Neupharma in collaboration with the non-profit company Rare Partners.